MOS
NVO

MGO One Seven’s Novo Nordisk NVO Stock Holding History

MGO One Seven’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$474K Buy
9,890
+2,101
+27% +$90.3K 0.01% 1000
2026
Q1 		$286K Sell
7,789
-1,210
-13% -$57.3K 0.01% 1154
2025
Q4 		$458K Sell
8,999
-16,037
-64% -$820K 0.01% 911
2025
Q3 		$1.39M Sell
25,036
-25,118
-50% -$1.47M 0.03% 499
2025
Q2 		$3.46M Buy
50,154
+32,432
+183% +$2.21M 0.11% 204
2025
Q1 		$1.23M Sell
17,722
-2,344
-12% -$194K 0.05% 387
2024
Q4 		$1.73M Buy
20,066
+2,413
+14% +$261K 0.07% 306
2024
Q3 		$2.1M Sell
17,653
-2,146
-11% -$286K 0.09% 241
2024
Q2 		$2.83M Buy
19,799
+3,629
+22% +$481K 0.13% 175
2024
Q1 		$2.08M Sell
16,170
-1,460
-8% -$174K 0.11% 212
2023
Q4 		$1.82M Buy
17,630
+600
+4% +$59.3K 0.1% 217
2023
Q3 		$1.55M Buy
17,030
+1,436
+9% +$126K 0.12% 194
2023
Q2 		$1.26M Sell
15,594
-912
-6% -$74.5K 0.12% 209
2023
Q1 		$1.31M Buy
16,506
+734
+5% +$52K 0.08% 254
2022
Q4 		$1.07M Buy
15,772
+150
+1% +$8.79K 0.11% 215
2022
Q3 		$778K Sell
15,622
-1,646
-10% -$88.2K 0.03% 290
2022
Q2 		$962K Sell
17,268
-9,156
-35% -$508K 0.13% 179
2022
Q1 		$1.13M Sell
26,424
-376
-1% -$19.3K 0.12% 193
2021
Q4 		$1.16M Buy
26,800
+2,064
+8% +$112K 0.12% 203
2021
Q3 		$1.03M Buy
24,736
+2,216
+10% +$107K 0.13% 194
2021
Q2 		$690K Buy
22,520
+332
+1% +$12.9K 0.1% 263
2021
Q1 		$544K Sell
22,188
-1,338
-6% -$47.7K 0.09% 278
2020
Q4 		$611K Buy
23,526
+6
+0% +$207 0.13% 217
2020
Q3 		$607K Sell
23,520
-370
-2% -$12.3K 0.14% 184
2020
Q2 		$585K Buy
23,890
+6,580
+38% +$210K 0.15% 187
2020
Q1 		$521K Buy
17,310
+1,062
+7% +$31.6K 0.18% 161
2019
Q4 		$470K Buy
+16,248
New +$450K 0.12% 229
2019
Q1 		– Sell
-2,004
Closed -$46K – 1227
2018
Q4 		$46K Buy
+2,004
New +$44.5K 0.02% 656
2018
Q1 		$56K Sell
2,288
-1,400
-38% -$36.8K 0.03% 585
2017
Q4 		$99K Buy
+3,688
New +$93.8K 0.05% 440

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $4.64B AUM 35.47% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

MGO One Seven's NVO Position: Q2 2026 in Review

MGO One Seven increased its Novo Nordisk (NVO) stake by 27% in Q2 2026, buying an estimated $90.3K and bringing the position to 9,890 shares worth $474K. The position accounts for 0.01% of the portfolio, ranked #1000.

MGO One Seven first reported a position in NVO in Q4 2017 and has held it in 30 quarters since. The position peaked at $3.46M in Q2 2025. 1,353 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • MGO One Seven held 9,890 shares of Novo Nordisk worth $474K as of Q2 2026.
  • MGO One Seven bought 2,101 Novo Nordisk shares in Q2 2026, an estimated $90.3K.
  • Novo Nordisk made up 0.01% of MGO One Seven's portfolio in Q2 2026, its #1000 holding.
  • MGO One Seven first reported a position in Novo Nordisk in Q4 2017 and has held it in 30 quarters since.
  • MGO One Seven's Novo Nordisk position peaked at $3.46M in Q2 2025.
  • 1,353 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on MGO One Seven's 13F filing for Q2 2026, filed 31 Jul 2026.